Prostate Cancer Foundation (PCF) Announces Inaugural Stupski Prize in Prostate Cancer Computational Oncology
$25,000 Awarded to Nikolaus Schultz, PhD for Work on cBioPortal
The prostate cancer Foundation (PCF) announced the Stupski Prize in Prostate Cancer Computational oncology, a first-in-field initiative designed to attract novel ideas to the rapidly changing field of large-scale cancer bioinformatics. These solutions will help clinicians and researchers optimize treatment for individual prostate cancer patients and may also lead to breakthroughs in other cancers as common molecular drivers and pathways are uncovered. A total of five $25,000 prizes will be awarded over the next two years.

Nikolaus Schultz, PhD, of Memorial Sloan Kettering Cancer Center, was named the inaugural Stupski Prize winner.
Prostate Cancer Foundation
"The Stupksi Prize creates prize philanthropy for cancer bioinformaticians in the same way we celebrate molecular biologists and clinical investigators who improve the patient's future. The Stupski Prize heightens the visibility of math and engineering in the health sciences, and underscores the importance of computational oncology for the treatment of genomically complex, life-threatening illnesses," says Jonathan W. Simons, MD, president and chief executive officer of PCF. "This initiative is truly a next-generation approach to saving lives."
Nikolaus Schultz, PhD, of Memorial Sloan Kettering Cancer Center, was named the inaugural Stupski Prize winner. Dr. Schultz's award recognizes his work in developing the cBioPortal for Cancer Genomics, a revolutionary web-based tool that provides visualization, analysis and download of large-scale cancer genomics data sets. He will be discussing the results of his work on Tuesday, April 21, 2015 at the annual meeting of the American Association for Cancer Research in Philadelphia, PA.
Dr. Schultz, who was named the 2014 John A. Paulson-PCF Young Investigator, is currently designing a computational software system that leverages the infrastructure of the cBioPortal to integrate patient-specific information, including genetic alterations, pathology results and treatment history, with population-scale cancer genome data. The resulting software will enable oncologists everywhere to identify relevant targetable alterations in individual prostate cancer patients, find available clinical trials for each patient and identify mechanisms of treatment resistance.
The next four prizes will be awarded as a result of global, crowdsourced competitions. PCF is calling for prospective participants to sign up for notifications on upcoming competitions through its website.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Transgene Receives FDA Fast Track Status for TG4010 for Treatment of Non-Small Cell Lung Cancer

Dräger AG Invests in Digital Health Startup GWA Hygiene - Digital hygiene solutions for hospitals
Sigma Life Science Announces Scientific Advisory Board to drive ADME/Tox program - Board to Provide Counsel on New Solutions for Pre-clinical Testing with Sigma’s CompoZr® Zinc Finger Nuclease (ZFN) Technology
New insight into cell receptors opens the way for tailored cancer drugs

Genetic Engineering without Unwanted Side-Effects Helps Fight Parasites - A live vaccine for toxoplasmosis

Nanostructures in human teeth

New infection mechanism in coronavirus discovered - Results provide starting point for development of antiviral therapies

New insights into lung tissue in Covid-19 disease - Researchers develop new three-dimensional imaging technique to visualize tissue damage in severe Covid-19
Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML

New biomarkers for coffee consumption
Experimental antibiotic treats deadly MRSA infection
